• Je něco špatně v tomto záznamu ?

Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohort

K. Mitrova, K. Cerna, K. Zdychyncova, B. Pipek, J. Svikova, P. Minarikova, M. Adamcova, J. David, M. Lukas, D. Duricova

. 2024 ; 183 (10) : 4243-4251. [pub] 20240718

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24018786
E-zdroje Online Plný text

NLK ProQuest Central od 1996-01-01 do Před 1 rokem
CINAHL Plus with Full Text (EBSCOhost) od 2012-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 1997-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1996-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1996-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 1996-01-01 do Před 1 rokem

Odkazy

PubMed 39023645
DOI 10.1007/s00431-024-05683-4
Knihovny.cz E-zdroje

Evidence on serological responses to vaccination in children exposed to ustekinumab (UST) or vedolizumab (VDZ) in utero is lacking. This multicentre prospective study aimed to assess the impact of prenatal exposure to UST or VDZ due to maternal inflammatory bowel disease (IBD) on serological responses to vaccination and other immunological parameters in exposed children. Children aged ≥ 1 year who were exposed in utero to UST or VDZ and completed at least 1-year of mandatory vaccination were included. We assessed the serological response to vaccination (non-live: tetanus, diphtheria, and Haemophilus influenzae B; live: mumps, rubella, and measles), whole blood count, and immunoglobulin levels. The control group comprised unexposed children born to mothers without IBD. A total of 23 children (median age, 25 months) exposed to UST (n = 13) or VDZ (n = 10) and 10 controls (median age, 37 months) were included. The serological response to vaccination was comparable between the UST and VDZ groups and controls, with an adequate serological response rate of ≥ 80%. Only children exposed to UST showed a slightly reduced serological response to mumps (67% vs. 86% in controls), whereas all children exposed to VDZ showed an adequate response. The majority of the exposed children had normal levels of individual immunoglobulin classes, similar to the controls. No severe pathology was observed in any of the children.Conclusion: Despite the limited sample size, our findings suggest that in utero exposure to VDZ or UST does not significantly impair the vaccine response or broader immunological parameters in exposed children.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24018786
003      
CZ-PrNML
005      
20241024111350.0
007      
ta
008      
241015s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00431-024-05683-4 $2 doi
035    __
$a (PubMed)39023645
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Mitrova, Katarina $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic. katarina.mitrova@fnmotol.cz $u Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06, Prague, Czech Republic. katarina.mitrova@fnmotol.cz $1 https://orcid.org/0000000218363745
245    10
$a Serological responses to vaccination in children exposed in utero to ustekinumab or vedolizumab: cross-sectional analysis of a prospective multicentre cohort / $c K. Mitrova, K. Cerna, K. Zdychyncova, B. Pipek, J. Svikova, P. Minarikova, M. Adamcova, J. David, M. Lukas, D. Duricova
520    9_
$a Evidence on serological responses to vaccination in children exposed to ustekinumab (UST) or vedolizumab (VDZ) in utero is lacking. This multicentre prospective study aimed to assess the impact of prenatal exposure to UST or VDZ due to maternal inflammatory bowel disease (IBD) on serological responses to vaccination and other immunological parameters in exposed children. Children aged ≥ 1 year who were exposed in utero to UST or VDZ and completed at least 1-year of mandatory vaccination were included. We assessed the serological response to vaccination (non-live: tetanus, diphtheria, and Haemophilus influenzae B; live: mumps, rubella, and measles), whole blood count, and immunoglobulin levels. The control group comprised unexposed children born to mothers without IBD. A total of 23 children (median age, 25 months) exposed to UST (n = 13) or VDZ (n = 10) and 10 controls (median age, 37 months) were included. The serological response to vaccination was comparable between the UST and VDZ groups and controls, with an adequate serological response rate of ≥ 80%. Only children exposed to UST showed a slightly reduced serological response to mumps (67% vs. 86% in controls), whereas all children exposed to VDZ showed an adequate response. The majority of the exposed children had normal levels of individual immunoglobulin classes, similar to the controls. No severe pathology was observed in any of the children.Conclusion: Despite the limited sample size, our findings suggest that in utero exposure to VDZ or UST does not significantly impair the vaccine response or broader immunological parameters in exposed children.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a prospektivní studie $7 D011446
650    _2
$a těhotenství $7 D011247
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a předškolní dítě $7 D002675
650    12
$a vakcinace $x škodlivé účinky $7 D014611
650    12
$a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a kojenec $7 D007223
650    12
$a zpožděný efekt prenatální expozice $x chemicky indukované $x imunologie $7 D011297
650    _2
$a průřezové studie $7 D003430
650    12
$a ustekinumab $x terapeutické užití $x škodlivé účinky $7 D000069549
650    12
$a idiopatické střevní záněty $x farmakoterapie $x imunologie $7 D015212
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a dítě $7 D002648
650    _2
$a gastrointestinální látky $x terapeutické užití $x škodlivé účinky $7 D005765
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Cerna, Karin $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic $u GENNET s.r.o., Prague, Czech Republic $1 https://orcid.org/0000000315935899 $7 xx0096040
700    1_
$a Zdychyncova, Kristyna $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic $1 https://orcid.org/0000000280241626
700    1_
$a Pipek, Barbora $u Digestive Diseases Centre, Hospital AGEL Vitkovice, Ostrava, Czech Republic $u 2nd Department of Internal Medicine Gastroenterology and Geriatrics, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic $1 https://orcid.org/0000000203158845
700    1_
$a Svikova, Jana $u Department of Internal Medicine, Jihlava Hospital, Jihlava, Czech Republic $1 https://orcid.org/0000000166369335 $7 xx0054190
700    1_
$a Minarikova, Petra $u Department of Medicine 1st Faculty of Medicine Charles University and Military Hospital, Military University Hospital Prague, Prague, Czech Republic
700    1_
$a Adamcova, Miroslava $u Private practice of General Pediatrician, Prague, Czech Republic
700    1_
$a David, Jan $u Department of Children and Adolescents, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic $1 https://orcid.org/0000000311312475
700    1_
$a Lukas, Milan $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic $1 https://orcid.org/0000000214633840 $7 jn19990202012
700    1_
$a Duricova, Dana $u IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic $u Department of Pharmacology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic $1 https://orcid.org/0000000260903522 $7 xx0118363
773    0_
$w MED00009638 $t European journal of pediatrics $x 1432-1076 $g Roč. 183, č. 10 (2024), s. 4243-4251
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39023645 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111344 $b ABA008
999    __
$a ok $b bmc $g 2201569 $s 1230759
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 183 $c 10 $d 4243-4251 $e 20240718 $i 1432-1076 $m European journal of pediatrics $n Eur J Pediatr $x MED00009638
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace